Polaryx Therapeutics Participates in NCL and NTSAD Events

News related to:Polaryx Therapeutics, Inc · 2 min read

PARAMUS, NJ, Nov. 20, 2026 /CourierPR/ -- Polaryx Therapeutics, a clinical-stage biotechnology company focused on developing patient-friendly small molecule and gene therapy treatments for rare orphan lysosomal storage disorders (LSDs), highlighted its participation in the 9th NCL Translational Science and Therapeutics Conference and the National Tay-Sachs & Allied Diseases Association’s (NTSAD) Imagine & Believe event in the Boston area. The company’s participation reflects its commitment to engaging with researchers, clinicians, patient advocates, and families as it advances development of its lead investigational drug candidate, PLX-200, across four rare pediatric LSDs.

At the NCL conference, held November 11-13, 2026, at the Marriott Boston Quincy in Quincy, Massachusetts, Will Charlton, M.D., M.A.S., Polaryx Therapeutics’ Chief Medical Officer, presented an update on the company’s development program, including previously published preclinical findings in a CLN3 mouse model. Polaryx was also represented by Shrijay Vijayan, Ph.D., MBA, Chief Scientific Officer, and the conference brought together scientists, clinicians, industry representatives, and patient advocacy organizations focused on advancing research and therapeutic development for neuronal ceroid lipofuscinoses (NCLs), commonly known as Batten disease. CLN2 and CLN3 disease are among the four indications being evaluated in Polaryx’s SOTERIA Phase 2 basket trial of orally administered PLX-200.

Members of the Polaryx team also attended NTSAD’s Imagine & Believe dinner on November 12, 2026, at the Hyatt Regency Boston/Cambridge. Polaryx supported the event as a sponsor. The annual fundraiser brings together families, researchers, industry representatives, and advocates to support research, family services, and advocacy for Tay-Sachs, Canavan, GM1, and Sandhoff diseases. Sandhoff disease is also one of the four indications included in SOTERIA.

Polaryx recently announced activation of the first SOTERIA clinical trial site at Boys Town National Research Hospital in Nebraska. SOTERIA is designed to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of PLX-200 in children with CLN2 disease, CLN3 disease, Krabbe disease, and Sandhoff disease, four different LSDs whose patient populations Polaryx believes represent approximately one quarter of the LSD population. SOTERIA is designed to be flexible, resource-efficient, and provide important data and information important to PLX-200’s future clinical development. Polaryx received a safe to proceed letter in October 2025 from the FDA and plans to initiate SOTERIA in the fourth quarter of 2026 in trial sites in the United States as well as in Europe and Asia or other foreign jurisdictions. Designed with a high degree of flexibility, SOTERIA represents a resource-efficient opportunity to validate PLX-200’s preclinical science across multiple LSDs while gathering data to inform planning PLX-200’s future development pathway, including the initiation of potentially pivotal trials. For the CLN2 and CLN3 cohorts, although the entire trial is open label, these cohorts will incorporate analyses comparing natural history data as a control arm to PLX-200’s treated arm. A natural history study is a preplanned observational study intended to track the course of the disease. Should the data demonstrate compelling clinical activity, Polaryx may pursue an expedited approval pathway. For more information about the SOTERIA trial, please visit clinicaltrials.gov/study/NCT07740512.

Polaryx Therapeutics, Inc.

Start filing today

One press release free every week. No card required.

Create a free account